Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Monte Rosa Therapeutics Inc (GLUE)

Monte Rosa Therapeutics Inc (GLUE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,487,295
  • Shares Outstanding, K 65,118
  • Annual Sales, $ 75,620 K
  • Annual Income, $ -72,700 K
  • EBIT $ 9 M
  • EBITDA $ 17 M
  • 60-Month Beta 1.60
  • Price/Sales 10.41
  • Price/Cash Flow N/A
  • Price/Book 5.78

Options Overview Details

View History
  • Implied Volatility 70.59% (-9.18%)
  • Historical Volatility 133.27%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 421.76% on 04/04/25
  • IV Low 70.59% on 01/23/26
  • Expected Move (DTE 26) 2.93 (12.84%)
  • Put/Call Vol Ratio 1.60
  • Today's Volume 65
  • Volume Avg (30-Day) 808
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 5,492
  • Open Int (30-Day) 10,344
  • Expected Range 19.91 to 25.77

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.45
  • Number of Estimates 3
  • High Estimate -0.41
  • Low Estimate -0.52
  • Prior Year 0.23
  • Growth Rate Est. (year over year) -295.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.69 +66.84%
on 01/06/26
25.77 -11.37%
on 01/08/26
+6.36 (+38.59%)
since 12/23/25
3-Month
10.21 +123.70%
on 10/24/25
25.77 -11.37%
on 01/08/26
+12.46 (+120.04%)
since 10/23/25
52-Week
3.50 +552.57%
on 04/07/25
25.77 -11.37%
on 01/08/26
+17.34 (+315.27%)
since 01/23/25

Most Recent Stories

More News
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering

BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc . (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based...

GLUE : 22.84 (-0.78%)
Stocks Settle Mostly Lower as Early Rally Fades

The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed down -0.34%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.94%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.06%. March E-mini...

MSTR : 163.11 (+1.32%)
B : 51.08 (+3.74%)
HL : 31.81 (+1.66%)
CDE : 26.11 (+1.32%)
JPM : 297.72 (-1.95%)
TXN : 193.31 (-0.86%)
$IUXX : 25,605.47 (+0.34%)
AMGN : 344.75 (-0.67%)
ZNH26 : 111-215s (+0.07%)
ESH26 : 6,945.75s (+0.01%)
GLUE : 22.84 (-0.78%)
STX : 346.10 (-0.12%)
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

BOSTON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc . (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based...

GLUE : 22.84 (-0.78%)
Stocks Hover Near Record Highs on Mixed US Economic News

The S&P 500 Index ($SPX ) (SPY ) today is up +0.10%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.36%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.34%. March E-mini S&P futures (ESH26...

MSTR : 163.11 (+1.32%)
AMAT : 322.38 (+1.13%)
B : 51.08 (+3.74%)
HL : 31.81 (+1.66%)
CDE : 26.11 (+1.32%)
JPM : 297.72 (-1.95%)
TXN : 193.31 (-0.86%)
$IUXX : 25,605.47 (+0.34%)
AMGN : 344.75 (-0.67%)
ZNH26 : 111-215s (+0.07%)
ESH26 : 6,945.75s (+0.01%)
GLUE : 22.84 (-0.78%)
Stocks Supported by Lower Bond Yields

The S&P 500 Index ($SPX ) (SPY ) today is up +0.13%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.10%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.18%. March E-mini S&P futures (ESH26...

MSTR : 163.11 (+1.32%)
AMAT : 322.38 (+1.13%)
B : 51.08 (+3.74%)
HL : 31.81 (+1.66%)
CDE : 26.11 (+1.32%)
ADI : 305.60 (-0.95%)
JPM : 297.72 (-1.95%)
MBLY : 9.80 (-6.76%)
TXN : 193.31 (-0.86%)
$IUXX : 25,605.47 (+0.34%)
AMGN : 344.75 (-0.67%)
ZNH26 : 111-215s (+0.07%)
Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects

In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated...

GLUE : 22.84 (-0.78%)
Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results

BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today...

GLUE : 22.84 (-0.78%)
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations

In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (4 of 4 patients) and a 100% disease control rate, including...

GLUE : 22.84 (-0.78%)
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results

BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today...

GLUE : 22.84 (-0.78%)
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases

Data support NEK7 as a potential novel and differentiated therapeutic approach to modulate the NLRP3 inflammasome in multiple cardiovascular and cardiometabolic diseases, including pericarditis and atherosclerosis...

GLUE : 22.84 (-0.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Monte Rosa Therapeutics Inc. is a biotechnology company. It involved in developing a portfolio of novel small molecule precision medicines which employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. Monte Rosa Therapeutics Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 24.80
2nd Resistance Point 24.37
1st Resistance Point 23.61
Last Price 22.84
1st Support Level 22.42
2nd Support Level 21.99
3rd Support Level 21.23

See More

52-Week High 25.77
Last Price 22.84
Fibonacci 61.8% 17.26
Fibonacci 50% 14.64
Fibonacci 38.2% 12.01
52-Week Low 3.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar